1Revenue declined 25.2% year-over-year to $12.5M, driven by U.S. generic competition for Endari® launched in 2024.
2Gross margin remained strong at 93.1%, with cost of goods sold declining proportionally to sales volume.
3Achieved operating income of $231k for FY2025, swinging from a $1.9M operating loss in FY2024, supported by reduced payroll expenses from headcount cuts.
4Net loss widened 16.1% year-over-year to $7.5M, with continued losses anticipated until Endari® sales or royalties increase.
5Net cash used in operating activities improved significantly to $11k for FY2025, down from $2.3M in FY2024, driven by working capital adjustments.
6Exclusive U.S. and Canadian Endari® license deal with NeoImmuneTech (NIT) is targeted to close following required regulatory approvals by October 1, 2026.
7U.S. selling expenses are expected to continue declining, with sales and marketing responsibilities set to transition to NIT upon deal close.